Multi-Agent Portfolio

# MAP Daily — 2026-09-23

## Snapshot
- Valor $9,603.80; cash $2,728.09; P&L día -$59.21 / -0.61%; retorno desde inception -3.962%; alpha vs SPY -3.2565 pp.

## Mercado
- SPY $767.81; +0.93% en 5 ruedas, pero cerró -0.72% en la rueda y quedó cerca del techo reciente.\n- La suba sigue selectiva: AI/megacaps sostienen el índice, mientras GOOGL y AMZN presionaron junto con yields y petróleo al alza.\n- No hubo confirmación técnica suficiente para volver a cargar riesgo; el book conserva liquidez.

## Acciones ejecutadas
- TRIM V 0.4 acciones (~$144.61) por breakdown confirmado bajo soporte.\n- HOLD en el resto; sin BUY/ADD. Cash alto es intencional: no se reemplazó la venta ni se persiguieron setups débiles.

## Contexto para mañana
- Vigilar recuperación de medias/soportes en V, GOOGL, AMZN y JPM.\n- Reabrir compras sólo con breakout confirmado y volumen; mantener ZYME como posición chica hasta ver conversión comercial.

# Debate MAP — 2026-09-23\n\n## Ronda 1 y Ronda 2\n- Sentiment: mercado selectivo; AI sostiene parte del tape, pero GOOGL/AMZN pesaron y el alza no confirma un risk-on amplio.\n- Quant: la mayoría de las posiciones están debajo de medias o sin breakout confirmado; V presenta breakdown de 20 sesiones y los scouts más fuertes llegan extendidos.\n- Fundamental: calidad alta en MSFT, GOOGL, AMZN, JPM, LLY, BRK-B y V; cautela en ZYME y biotechs/eventos por ejecución o binarios.\n\n## Risk\n- Veto absoluto a BUY/ADD en todo el universo esta ronda. Recomienda TRIM parcial de V por ruptura confirmada debajo de soporte; el resto, HOLD/PASS.\n\n## Scorecard\n- **MSFT** — CS 0.7780 (Q 0.81 / F 0.84 / S 0.64) → **PASS** · VETO Risk: Current holding is near its 12% target allocation, while Quant reports no confirmed breakout and price remains below resistance. Fundamental quality is strong, but Risk does not permit adding without clearer confirmation.\n- **BRK-B** — CS 0.5675 (Q 0.43 / F 0.83 / S 0.42) → **PASS** · VETO Risk: Diversification and valuation support the existing position, but the five-day tape is negative, price is just below MA20 and no breakout is confirmed. The setup favors holding rather than increasing exposure.\n- **GOOGL** — CS 0.5540 (Q 0.23 / F 0.87 / S 0.63) → **PASS** · VETO Risk: High-volume weakness, price below MA20 and proximity to reported support create adverse timing risk despite strong fundamentals. Hold the existing position; do not add until MA20 recovery or support confirmation.\n- **MG** — CS 0.5525 (Q 0.45 / F 0.65 / S 0.58) → **PASS** · VETO Risk: The reported all-cash transaction provides event support, but no validated price, volume or spread metrics are supplied and approval, financing, go-shop and closing risks remain. Do not initiate without measurable spread and risk data.\n- **CBZ** — CS 0.5390 (Q 0.44 / F 0.63 / S 0.57) → **PASS** · VETO Risk: The reported approximately $55 all-cash acquisition is capped by the consideration and lacks validated technical, spread and liquidity data. Shareholder, regulatory and closing risks prevent a new position.\n- **LLY** — CS 0.5290 (Q 0.25 / F 0.79 / S 0.61) → **PASS** · VETO Risk: Strong operating quality and a constructive five-day return are offset by price just below MA20, RSI 46.71, no confirmed breakout and substantial valuation and execution risk. Preserve the core holding and wait for confirmation before adding.\n- **JPM** — CS 0.5070 (Q 0.42 / F 0.79 / S 0.25) → **PASS** · VETO Risk: The position has already been reduced toward its 8% target, but price is at reported 20-day support while the five-day tape is negative and RSI is 30.96. Oversold status is not confirmation; no new exposure.\n- **AMZN** — CS 0.5050 (Q 0.22 / F 0.82 / S 0.52) → **PASS** · VETO Risk: Price is below MA20, RSI is weak, volume is elevated and reported support is only 2.034% lower. The business thesis remains intact, but the technical risk and prior trims do not justify a new add.\n- **XOM** — CS 0.4840 (Q 0.36 / F 0.70 / S 0.38) → **PASS** · VETO Risk: The one-day rebound has not repaired the negative five-day trend; price remains below MA20 with weak RSI and below-average volume. Geopolitical or oil narratives do not override the current tape risk.\n- **AMRX** — CS 0.4710 (Q 0.41 / F 0.57 / S 0.43) → **PASS** · VETO Risk: FDA approval and launch provide a tangible catalyst, but the stock had a sharp down day after a strong run, while thin margins, competition and post-catalyst execution risk remain. Wait for stabilization or confirmed continuation.\n- **VICR** — CS 0.4670 (Q 0.35 / F 0.62 / S 0.44) → **PASS** · VETO Risk: Although the 20-day breakout is confirmed, the supplied tape is severely extended: RSI 81.27, +53.916% over five days and 43.454% above MA20. Valuation and concentration risks make chasing unacceptable.\n- **OSCR** — CS 0.4260 (Q 0.24 / F 0.65 / S 0.41) → **PASS** · VETO Risk: Reported growth and guidance are constructive, but the stock has a negative day and five-day return, sits below MA20 and has a high-volume breakdown classification in the supplied debate. Require technical repair and margin/medical-cost confirmation.\n- **MIRM** — CS 0.4065 (Q 0.30 / F 0.49 / S 0.46) → **PASS** · VETO Risk: Positive Phase 2 data and an imminent PDUFA are genuine catalysts, but the FDA decision, label and safety remain binary risks and no technical series is available. Pre-decision entry is vetoed.\n- **V** — CS 0.3950 (Q 0.17 / F 0.77 / S 0.23) → **PASS** · VETO Risk: Quant confirms a 20-day breakdown with price below reported support, alongside a negative day and five-day return. Strong network fundamentals do not offset the confirmed deterioration; reduce risk and do not add until support is reclaimed.\n- **EWTX** — CS 0.3895 (Q 0.33 / F 0.40 / S 0.47) → **PASS** · VETO Risk: The case relies mainly on an analyst target increase; supplied data do not establish trend, volume, support, clinical validation or a commercial earnings base. Biotech execution and approval risk are not acceptable for a new entry.\n- **ZYME** — CS 0.2960 (Q 0.31 / F 0.27 / S 0.31) → **PASS** · VETO Risk: The runner is already limited near its 3% target after prior trims. Despite a rebound, price remains below MA20, RSI is 40.02 and volume ratio is only 0.72; weak fundamentals and low participation prohibit adding.\n- **GRAL** — CS 0.2495 (Q 0.38 / F 0.00 / S 0.39) → **PASS** · VETO Risk: Both reported breakouts are accompanied by RSI 85.31, a +42.95% five-day move, 34.334% extension above MA20 and very high volume. The breakout is real but the entry is materially extended and reversal-prone.\n- **KOD** — CS 0.1845 (Q 0.28 / F 0.00 / S 0.29) → **PASS** · VETO Risk: The expected Phase 3 readout is a binary catalyst with unresolved dose, durability, efficacy and safety outcomes, and no validated technical series is supplied. Do not take pre-event gap risk.\n- **SPY** — CS 0.1400 (Q 0.00 / F 0.00 / S 0.56) → **PASS** · VETO Risk: Broad-market sentiment is selectively constructive, but SPY is immediately below resistance on below-average volume with no confirmed breakout. This is context, not a sufficient risk-on confirmation for a new allocation.\n- **DHT** — CS 0.1200 (Q 0.00 / F 0.00 / S 0.48) → **PASS** · VETO Risk: The supplied sentiment report cites strong tanker-cycle economics and a healthy structure, but also a sharp daily reversal, negative five-day tape and no breakout. With no corroborating Quant or Fundamental entry data supplied, do not initiate.

# Decisiones MAP — 2026-09-23\n\n## Acciones\n- TRIM V 0.4 acciones @ $361.52 (~$144.61): breakdown confirmado debajo de soporte; se reduce riesgo sin recomprar.\n- HOLD resto; no se fuerza reemplazo ni full deploy. Cash queda intencionalmente alto.\n\n## Scorecard\n- **MSFT** — CS 0.7780 (Q 0.81 / F 0.84 / S 0.64) → **PASS** · VETO Risk: Current holding is near its 12% target allocation, while Quant reports no confirmed breakout and price remains below resistance. Fundamental quality is strong, but Risk does not permit adding without clearer confirmation.\n- **BRK-B** — CS 0.5675 (Q 0.43 / F 0.83 / S 0.42) → **PASS** · VETO Risk: Diversification and valuation support the existing position, but the five-day tape is negative, price is just below MA20 and no breakout is confirmed. The setup favors holding rather than increasing exposure.\n- **GOOGL** — CS 0.5540 (Q 0.23 / F 0.87 / S 0.63) → **PASS** · VETO Risk: High-volume weakness, price below MA20 and proximity to reported support create adverse timing risk despite strong fundamentals. Hold the existing position; do not add until MA20 recovery or support confirmation.\n- **MG** — CS 0.5525 (Q 0.45 / F 0.65 / S 0.58) → **PASS** · VETO Risk: The reported all-cash transaction provides event support, but no validated price, volume or spread metrics are supplied and approval, financing, go-shop and closing risks remain. Do not initiate without measurable spread and risk data.\n- **CBZ** — CS 0.5390 (Q 0.44 / F 0.63 / S 0.57) → **PASS** · VETO Risk: The reported approximately $55 all-cash acquisition is capped by the consideration and lacks validated technical, spread and liquidity data. Shareholder, regulatory and closing risks prevent a new position.\n- **LLY** — CS 0.5290 (Q 0.25 / F 0.79 / S 0.61) → **PASS** · VETO Risk: Strong operating quality and a constructive five-day return are offset by price just below MA20, RSI 46.71, no confirmed breakout and substantial valuation and execution risk. Preserve the core holding and wait for confirmation before adding.\n- **JPM** — CS 0.5070 (Q 0.42 / F 0.79 / S 0.25) → **PASS** · VETO Risk: The position has already been reduced toward its 8% target, but price is at reported 20-day support while the five-day tape is negative and RSI is 30.96. Oversold status is not confirmation; no new exposure.\n- **AMZN** — CS 0.5050 (Q 0.22 / F 0.82 / S 0.52) → **PASS** · VETO Risk: Price is below MA20, RSI is weak, volume is elevated and reported support is only 2.034% lower. The business thesis remains intact, but the technical risk and prior trims do not justify a new add.\n- **XOM** — CS 0.4840 (Q 0.36 / F 0.70 / S 0.38) → **PASS** · VETO Risk: The one-day rebound has not repaired the negative five-day trend; price remains below MA20 with weak RSI and below-average volume. Geopolitical or oil narratives do not override the current tape risk.\n- **AMRX** — CS 0.4710 (Q 0.41 / F 0.57 / S 0.43) → **PASS** · VETO Risk: FDA approval and launch provide a tangible catalyst, but the stock had a sharp down day after a strong run, while thin margins, competition and post-catalyst execution risk remain. Wait for stabilization or confirmed continuation.\n- **VICR** — CS 0.4670 (Q 0.35 / F 0.62 / S 0.44) → **PASS** · VETO Risk: Although the 20-day breakout is confirmed, the supplied tape is severely extended: RSI 81.27, +53.916% over five days and 43.454% above MA20. Valuation and concentration risks make chasing unacceptable.\n- **OSCR** — CS 0.4260 (Q 0.24 / F 0.65 / S 0.41) → **PASS** · VETO Risk: Reported growth and guidance are constructive, but the stock has a negative day and five-day return, sits below MA20 and has a high-volume breakdown classification in the supplied debate. Require technical repair and margin/medical-cost confirmation.\n- **MIRM** — CS 0.4065 (Q 0.30 / F 0.49 / S 0.46) → **PASS** · VETO Risk: Positive Phase 2 data and an imminent PDUFA are genuine catalysts, but the FDA decision, label and safety remain binary risks and no technical series is available. Pre-decision entry is vetoed.\n- **V** — CS 0.3950 (Q 0.17 / F 0.77 / S 0.23) → **PASS** · VETO Risk: Quant confirms a 20-day breakdown with price below reported support, alongside a negative day and five-day return. Strong network fundamentals do not offset the confirmed deterioration; reduce risk and do not add until support is reclaimed.\n- **EWTX** — CS 0.3895 (Q 0.33 / F 0.40 / S 0.47) → **PASS** · VETO Risk: The case relies mainly on an analyst target increase; supplied data do not establish trend, volume, support, clinical validation or a commercial earnings base. Biotech execution and approval risk are not acceptable for a new entry.\n- **ZYME** — CS 0.2960 (Q 0.31 / F 0.27 / S 0.31) → **PASS** · VETO Risk: The runner is already limited near its 3% target after prior trims. Despite a rebound, price remains below MA20, RSI is 40.02 and volume ratio is only 0.72; weak fundamentals and low participation prohibit adding.\n- **GRAL** — CS 0.2495 (Q 0.38 / F 0.00 / S 0.39) → **PASS** · VETO Risk: Both reported breakouts are accompanied by RSI 85.31, a +42.95% five-day move, 34.334% extension above MA20 and very high volume. The breakout is real but the entry is materially extended and reversal-prone.\n- **KOD** — CS 0.1845 (Q 0.28 / F 0.00 / S 0.29) → **PASS** · VETO Risk: The expected Phase 3 readout is a binary catalyst with unresolved dose, durability, efficacy and safety outcomes, and no validated technical series is supplied. Do not take pre-event gap risk.\n- **SPY** — CS 0.1400 (Q 0.00 / F 0.00 / S 0.56) → **PASS** · VETO Risk: Broad-market sentiment is selectively constructive, but SPY is immediately below resistance on below-average volume with no confirmed breakout. This is context, not a sufficient risk-on confirmation for a new allocation.\n- **DHT** — CS 0.1200 (Q 0.00 / F 0.00 / S 0.48) → **PASS** · VETO Risk: The supplied sentiment report cites strong tanker-cycle economics and a healthy structure, but also a sharp daily reversal, negative five-day tape and no breakout. With no corroborating Quant or Fundamental entry data supplied, do not initiate.